Summary:
-
Innovative Cancer Therapy
Researchers at Stanford have developed a novel approach that tricks cancer cells into self-destructing by activating their natural cell death processes. -
Mechanism of Action
The method involves artificially linking two proteins, BCL6 and CDK9, to switch on apoptosis-promoting genes that are usually suppressed by BCL6 in cancer cells. -
Promising Lab Results
In laboratory tests, the new compound was highly effective at killing diffuse large B-cell lymphoma cells without causing significant toxicity to healthy cells. -
Targeted Specificity
The technique specifically targets lymphoma cells, as BCL6 is primarily present in these cells, making the therapy potentially less harmful to other types of cells. -
Future Directions
The researchers have co-founded Shenandoah Therapeutics to advance their findings toward clinical trials and explore similar compounds for targeting other cancer-driving proteins.
Read more at: Stanford Medicine